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Introduction
Gaucher disease type 1 is an inherited lysosomal disorder characterized by deficient activity of the enzyme acid β-glucosidase with consequential accumulation of the substrate, glucosylceramide, and its unacylated derivative, glucosylsphingosine, primarily in lysosomes of tissue macrophages. 1 Pathological accumulation of these glycosphingolipids is associated with multisystemic disease manifestations, most notably hepatosplenomegaly, accompanied by anemia, thrombocytopenia, and bone disease. 1 For 25 years, enzyme replacement therapy for Gaucher disease type 1 has been the mainstay of treatment. This usually involves alternate-week infusions of recombinant mannose-terminated human acid β-glucosidase, which is targeted to the pathological macrophages; here it augments the residual enzyme activity to enhance recycling of β-glucosylceramide. Enzyme therapy can reverse the hematological and visceral complications of the disease and can prevent bone damage; it improves the quality-of-life for people with Gaucher disease. [2] [3] [4] [5] Eliglustat is an oral substrate reduction therapy approved in the United States in 2014 and European Union in 2015
for adults with Gaucher disease type 1 who are extensive, intermediate, or poor CYP2D6 metabolizers (>90% of patients). Eliglustat acts by partially inhibiting the de novo biosynthesis of β-glucosylceramide, thereby rebalancing the rate of formation of the primary substrate of the deficient enzyme with its impaired degradation. In clinical Phase 2 and 3 studies of previously untreated patients with Gaucher disease type 1, eliglustat induced clinically meaningful improvements in hematological parameters as well as spleen and liver volumes at 9-12 months, 6, 7 which were maintained at 18 months 8 and after 4 years. 9 Bone mineralization density also improved after 1 year of eliglustat therapy. 8, 10, 11 In the Phase 3 ENCORE trial (NCT00943111) of eliglustat treatment for patients with Gaucher disease type 1 already stabilized with enzyme therapy, after one year of treatment, eliglustat was found to be non-inferior to imiglucerase in maintaining stable platelet and hemoglobin parameters, as well as spleen and liver volumes. 12 Bone parameters and quality-of-life measures also remained stable. 12 After the 12-month primary analysis period, patients were offered enrollment in a long-term extension phase during which all received eliglustat. Here we report the safety and efficacy outcomes from the ENCORE trial over this period.
Methods

Study Design
The ENCORE clinical trial was a randomized, multinational, open-label, non-inferiority study comparing eliglustat (Cerdelga Gaucher disease type 1 who had already achieved therapeutic goals while receiving enzyme therapy. Detailed methods and the primary outcomes from ENCORE were published previously. 12 All long-term efficacy and safety analyses were done on the intent-to-treat population. As in the primary analysis, dosing was individualized and based on achieving plasma trough levels of at least 5 ng/mL (with doses of 50, 100, or 150 mg eliglustat tartrate twice daily); since the Cerdelga product label refers to active base, this corresponds to doses of 42, 84, and 127 mg, respectively. After the 12-month primary analysis period, all patients had the option of continuing in the open-label extension phase of the trial, in which they were treated with eliglustat (i.e., patients initially randomized to imiglucerase were switched to eliglustat) and followed until the pre-determined end of the study in May, 2015. Thus, patients had the opportunity to be treated with eliglustat for 2 to 4.5 years. This was determined by when they enrolled (enrollment spanned 2 years, from September 2009 until November 2011), the initial treatment group to which they were randomly assigned, and their country of residence. After approval of the drug by the United States Food and Drug Administration in the fall of 2014, trial participants living in the United States were discontinued from the study and transitioned to commercial eliglustat.
In the analysis of long-term treatment with eliglustat, baseline was defined as the last available assessment prior to eliglustat treatment initiation (Day 1 for patients originally randomized to eliglustat and Week 52 + 1 Day for patients originally randomized to imiglucerase). All data were analyzed with respect to time on eliglustat treatment rather than time in the trial. Patients
were not distinguished on the basis of their original treatment allocation since all patients, including those randomized to receive imiglucerase, were receiving enzyme therapy before switching to eliglustat.
Here we report long-term safety and efficacy with respect to years of exposure for all 157
eliglustat-treated patients in ENCORE; in 46 of these, trial data are available for a period of 4 years.
Assessments
The following parameters were evaluated as described previously: hemoglobin concentration, 12 For these analyses, values were examined at the baseline before eliglustat was given, and after 1, 2, 3, and 4 years of treatment with the agent. Adverse events are summarized by their incidence, seriousness, severity, and relationship to eliglustat and to underlying disease.
Analysis of Disease Stability
As described previously, 12 the composite primary efficacy endpoint of the ENCORE trial was the percentage of patients whose hematological parameters and organ volumes remained stable after 12 months. The stability criteria were defined as those established for these measures in patients with Gaucher disease type 1 receiving maintenance treatment with imiglucerase: 13 hemoglobin concentration that did not decrease by more than 1.5 g/dL; platelet count that did not decrease by more than 25%; spleen volume (in non-splenectomized subjects expressed as multiples of normal, MN) that did not increase by more than 25%; and liver volume (MN) that did not increase by more than 20% from baseline.
We also determined whether patients met the following pre-specified therapeutic goals for hemoglobin, platelet, spleen, and liver parameters based on trial entry criteria and established therapeutic goals for patients receiving enzyme therapy [13] [14] [15] : hemoglobin ≥11.0 g/dL for women and ≥ 12.0 g/dL for men; platelet count ≥10 9 /L; spleen volume ≤ 8 MN; and liver volume ≤ 1.5
MN.
Statistical Analysis
The analyses include all patients who were treated with eliglustat and were carried out with Adverse events are set out in terms of relatedness to eliglustat treatment. In particular, events deemed related by investigators that occurred in more than 5% of patients are presented by number of patients as well as the number of events. Percentages of patients in each category
were calculated from the total number treated with eliglustat in the one-year primary analysis study or during the extension period. Compliance was determined by the number of pills that were returned at each study visit.
Results
Patient Disposition and Characteristics
Of 157 to those for all eliglustat-treated patients who entered the trial ( Table 1) .
Maintenance of Stable Gaucher Disease Hematological and Visceral Parameters
Throughout the trial, mean values for hemoglobin concentration, platelet count, spleen volume, and liver volume remained stable among all eliglustat-treated patients and in the subset of patients who had 4-year data ( Figure 2 , A-D), with no clinically significant changes from the baseline values attained after a mean of 10 years of enzyme therapy. There were small but statistically significant reductions in least-square mean liver (3%, P=0.02) and spleen volumes (13%, P<0.001) after 4 years of eliglustat treatment (Table 2) . With respect to the primary and secondary clinical endpoints, year to year, all four measures remained collectively stable (composite primary endpoint relative to baseline values) in ≥85% of patients and individually in ≥92% of patients (secondary endpoints) ( Figure 3A) . With respect to pre-specified therapeutic goals established for patients on enzyme therapy, 14, 15 thresholds for hemoglobin, platelets, spleen, and liver were maintained collectively in ≥92% of patients and each individual goal was maintained in ≥94% of patients ( Figure 3B ).
Most patients who did not achieve the primary composite endpoint missed on a single criterion, and this group varied from year to year. Only one patient missed more than two criteria at once; this patient missed spleen, platelets, and liver at one time point. Among patients with at least 2 years on eliglustat, six patients missed the composite endpoint at all time points (five consistently missed the platelet endpoint, three patients missed the spleen endpoint one or more times, and one patient missed the liver endpoint one time). No common clinical characteristics in this group were identified. The logistic regression analysis found no correlation between age, gender, splenectomy status, or obesity status with inability to meet the composite endpoint.
Maintenance of Stable Bone Mineral Density
Active bone disease was an exclusion criterion for this trial; patients could not have experienced bone crisis or symptomatic bone disease (bone pain attributable to osteonecrosis or pathological fractures within the year before randomization). 12 Mean baseline bone mineral density scores for the lumbar spine and femur were found to be within the age-matched reference range for healthy individuals. These values were maintained throughout the 4 years of eliglustat treatment ( Figure 2 , E and F). Of note, after 4 years of treatment with eliglustat, lumbar spine least-square mean Zscores increased by 0.29 (P<0.0001) ( Table 2) .
Biomarkers, Gaucher Disease Severity, and Quality-of-Life
The respective activity measures and concentrations of disease-related biomarkers are set out in Table 3 . Median activities of chitotriosidase and concentrations of macrophage inflammatory protein 1β were elevated at baseline and decreased modestly over 4 years. Plasma concentrations of GL-1 and GM3 ganglioside were in the healthy reference range at baseline but decreased by >50% during the first 3 months of exposure to eliglustat, consistent with the systemic action and diffusible nature of this agent; thereafter these biomarkers remained stable and within the healthy normal range over the period of investigation up to 4 years. Median concentrations of the bioactive sphingolipids, ceramide and sphingomyelin, were in the normal reference range at baseline; over 4 years, ceramide was unchanged and sphingomyelin increased slightly but remained well within the normal reference range for healthy subjects.
No clinically significant changes in any Gaucher disease or quality-of-life measures were observed over 4 years. The mean baseline Fatigue Severity Scale score was 3.0 (1=least severe, 7=most severe) and remained between 3.0 and 3.2 (median scores ranged from 2.7 to 2.9). The mean baselines for the SF-36 mental and physical component scores were 52 and 51, respectively (mean score for a normal comparator population=50); both remained between 50
and 51 (median scores ranged from 52 to 56). For the Brief Pain Inventory, mean average pain score at baseline was 1.4 (0=non-interference, 10=maximal interference) and remained between 1.4 and 1.6 (median score remained between 0 and 1). For the Gaucher Disease Severity Scoring System (DS3), the mean total baseline score was 2.2 (0=best, 19=worst score) and remained between 2.0 to 2.3 (median was 2.0 at all time points). At baseline, 95% of patients reported unrestricted mobility, and this percentage remained between 95% and 97% year to year. Three (2%) patients reported a bone crisis while being treated with eliglustat, including one patient who also had a bone crisis at baseline. Of the 141 patients who responded to a treatment preference survey (oral versus intravenous enzyme treatment) after 1 year of eliglustat, 98% expressed a preference for oral therapy; the main reason cited was "convenience." Of the three patients who did not prefer oral treatment, two were undecided and one preferred intravenous treatment because it is given in hospital.
Compliance
Overall, 90% of patients took ≥90% of their pills, 6% took ≥80 to <90% of their pills, 3% took ≥70 to <80%, and 2% took ≥40 to <60% of their pills.
Adverse Events
The adverse event data set out in Table 4 reflect 511 patient-years of exposure to eliglustat.
Seventy-four percent of adverse events were mild, 23% were moderate, and 3% were considered severe. Four (2.5%) patients withdrew for adverse events considered related to eliglustat, all of which occurred during the patients' first 9 months of eliglustat treatment and all resolved: mild lethargy and exfoliative rash (0.1 years), severe upper abdominal pain (0.3 years), moderate palpitations (0.54 years) with no clinically relevant ECG findings, and mild vertigo (0.83 years).
Two serious adverse events considered possibly related to eliglustat by the investigator occurred in two patients; neither led to withdrawal from the study: one moderate event of peripheral neuropathy and one severe event of bowel obstruction due to Meckel's diverticulum.
Discussion
The primary analysis from the ENCORE trial clearly showed that eliglustat was non-inferior to imiglucerase in its capacity to maintain parameters indicating disease that was stable for 1 year. 12 The analysis reported here, representing 511 patient-years of eliglustat exposure, shows long term safety and tolerability along with stable disease parameters and maintenance of therapeutic goals for up to 4 years in the cohort of patients assigned to receive eliglustat and the original imiglucerase cohort who later moved to eliglustat treatment after participation in the first year of the trial. Mean absolute values for hemoglobin concentration, platelet count, spleen volume, liver volume, and lumbar spine and femur Z-scores remained stable over 4 years. While, for the reasons set out, the number of patients available for analysis after 4 years of treatment under the constraints of a clinical trial was considerably reduced, the statistical analysis using a repeated measures mixed model to detect linear trends identified modest but statistically significant improvements in spleen volume, liver volume, and lumbar spine Z-scores. While these results should be interpreted cautiously because of the fewer patients from whom 4-year data are available, analysis of the response parameters in this subset reveals the same long-term trends as in the trial cohort.
Biomarkers reflecting Gaucher disease activity were also found to be stable or showed modest improvement over time. Quality-of-life measures, which indicated a relatively mild burden of disease at baseline, also remained stable for up to 4 years in patients receiving eliglustat,
indicating that the quality-of-life that they had achieved after a mean of 10 years on enzyme therapy was maintained while they were taking eliglustat therapy in the long term.
Only 4 patients (2.5%) withdrew from this long-term trial due to adverse events considered to be treatment related; no patient withdrew from the study because of any significant clinical deterioration. Most patients who did not meet the primary composite trial endpoint of stability relative to their baseline values remained clinically stable, as evidenced by the higher proportion of patients year to year who maintained absolute values within the pre-specified thresholds for therapeutic goals (Figure 3 ). Because trial stability goals were defined relative to each patient's individual baseline, patients could (and often did) fail to meet the composite endpoint due to a clinical value that did not signify deterioration. For example, a patient whose baseline liver volume increased from 0.9 multiples of normal (MN) at baseline to 1.1 MN would fail to meet the composite endpoint, as this represents a >20% increase in liver volume, despite the fact that the actual value of 1.1 is well within established therapeutic goals for Gaucher patients. There were no apparent predictors of inability to meet the composite trial endpoint, including age, sex, and splenectomy status. Obesity was also evaluated, due to the possibility that drug distribution could be lower in obese individuals.
No new safety concerns were identified in this long-term trial; this is consistent with a combined analysis of adverse event data from all four phase 2 and 3 eliglustat clinical trials. 16 Only seven types of adverse events considered related to treatment by the investigator were reported in 5% or more of patients, with the most common being upper abdominal pain, reported in 7% of patients. Three of the seven most common related adverse events in the trial are also known to be common in Gaucher disease: fatigue, arthralgia, and abnormal nerve conduction studies. Of note, as in all clinical trials of eliglustat hitherto, we did not see the pattern of chronic diarrhea, weight loss, or new tremor, which led to high rates of drug discontinuation in clinical trials of miglustat (Zavesca, Actelion, Allschwil, Switzerland), the first commercially available substrate reduction therapy, approved as a second-line treatment for adults with Gaucher disease who are not candidates for enzyme therapy. 17, 18 Despite the salutary findings of this study, we recognize that there are a few inherent limitations.
During the long-term extension phase of ENCORE, there was no comparator group because all patients were taking eliglustat, thus no direct comparison can be made over this period with patients who continue to receive long-term enzyme therapy. Although it has been suggested that relapse is uncommon once patients with Gaucher disease type 1 have had their bulk disease controlled with enzyme therapy, 19 the effects of the constrained supply of imiglucerase in [2009] [2010] [2011] [2012] show that clinical deterioration does occur in as little as 3 months with treatment interruption. 20, 21 In our study, clinical stability was maintained with respect to hemoglobin concentration, platelet count, liver and spleen volume, bone mineral density and Gaucher biomarkers for up to 4 years, well beyond the interval that might be attributed to residual effects of prior long-term enzyme replacement therapy. Although we are encouraged by the long-term maintenance of bone health, because the population had no active bone disease at baseline, data from this trial do not address the question of whether eliglustat can reverse pre-existing bone disease.
Patients with Gaucher disease are known to be at increased risk of both Parkinson disease and hematologic malignancies. 22, 23 It will be important to evaluate the impact (if any) of eliglustat on incidence of these concomitant diseases in long-term observational studies; however, since the drug does not cross the blood-brain barrier, we would not expect a salutary effect of eliglustat on
Parkinson disease.
Long-term eliglustat compliance was good, with 96% of patients taking at least 80% of their pills. Notably, this long-term analysis included all eliglustat-treated patients, unlike in the primary efficacy analysis, which, as a non-inferiority trial, had excluded two patients whose study drug compliance was less than 80%. It will be important to monitor "real world"
compliance and its impact on drug efficacy, as compliance rates are likely to decrease outside of a clinical trial setting.
Like many other oral drugs, eliglustat is metabolized primarily through the cytochrome P450 2D6 (CYP2D6) pathway. Dosing in the eliglustat trials was titrated with the aim of maintaining a plasma trough level ≥5 ng/ml, at which half-maximal inhibition of glucosylceramide synthase is predicted to occur. However, subsequent pharmacokinetic analyses of clinical trial data established that the major determinant of plasma trough level of eliglustat was the patient's CYP2D6-metabolizer status, and that achievement of the target 5 ng/ml level was not necessary for drug efficacy. 24 Therefore, dosing in the drug label is based on the predicted CYP2D6 phenotype, as determined by genetic testing. The label also makes recommendations with regard to concomitant medications that might either inhibit efficacy of eliglustat or increase plasma drug levels. 25, 26 As in the general population, 27 approximately 90% of patients with Gaucher disease are intermediate or extensive CYP2D6 metabolizers, with the remainder being poor metabolizers, ultra-rapid metabolizers, or unknown. Of note, the ENCORE trial included seven patients with an ultra-rapid CYP2D6 metabolizer genotype, for whom eliglustat would be contraindicated in drug labels due to insufficient information about this small patient subgroup;
all seven of these patients met the primary composite endpoint throughout the trial.
We conclude that clinical stability, judged by composite and individual measures, was maintained in eliglustat-treated patients with Gaucher disease type 1 who remained in the ENCORE trial for up to 4 years. Eliglustat was generally well-tolerated and no new or long-term safety concerns were identified.
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Figure legend: The N's for each year represent the number of overall patients in the trial at that time point. The number of patients represented for each individual assessment varied slightly and were lower for spleen measures as they excluded splenectomized patients.
